21 October 2025 - Gilead Sciences today announced that Health Canada has approved Lyvdelzi (seladelpar) for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have had an inadequate response to ursodeoxycholic acid alone, or as monotherapy in patients unable to tolerate ursodeoxycholic acid. 

This market authorisation has been issued with conditions pending the results of trials to verify its clinical benefit.

Read Gilead press release